Antithrombotic activity of Bay u3405, a thromboxane A2-antagonist, in patients with Dacron aortic grafts: a random controlled clinical trial.
Identifieur interne : 004D85 ( Main/Exploration ); précédent : 004D84; suivant : 004D86Antithrombotic activity of Bay u3405, a thromboxane A2-antagonist, in patients with Dacron aortic grafts: a random controlled clinical trial.
Auteurs : RBID : pubmed:8165609English descriptors
- KwdEn :
- Aged, Aorta, Blood Platelets (cytology), Blood Platelets (physiology), Blood Vessel Prosthesis, Carbazoles (pharmacology), Cell Survival, Double-Blind Method, Follow-Up Studies, Humans, Indium Radioisotopes (diagnostic use), Male, Middle Aged, Platelet Adhesiveness (drug effects), Polyethylene Terephthalates, Sulfonamides (pharmacology), Thromboxane A2 (antagonists & inhibitors).
- MESH :
- chemical , antagonists & inhibitors : Thromboxane A2.
- chemical , diagnostic use : Indium Radioisotopes.
- chemical , pharmacology : Carbazoles, Sulfonamides.
- cytology : Blood Platelets.
- drug effects : Platelet Adhesiveness.
- physiology : Blood Platelets.
- Aged, Aorta, Blood Vessel Prosthesis, Cell Survival, Double-Blind Method, Follow-Up Studies, Humans, Male, Middle Aged, Polyethylene Terephthalates.
Abstract
Twelve patients with Dacron aortic grafts participated in a placebo controlled, crossover trial to investigate the effect of Bay u3405, a thromboxane A2 receptor antagonist, on graft thrombogenicity. During each treatment period (seven days, Bay u3405 or placebo), 111In-platelet survival and platelet deposition on the grafts were measured daily by gamma-camera imaging and blood radioactivity analysis. Bay u3405 substantially reduced the deposition of platelets and the thrombogenic index, while platelet survival remained unchanged. The ex vivo platelet aggregation response to ADP and epinephrine was significantly inhibited. The bleeding time increased slightly but not to any clinically relevant extent, and no adverse side effects were recorded. Bay u3405 seems to be a safe and effective drug for the inhibition of platelet deposition on aortic Dacron grafts. The use of quantitative imaging techniques is also more sensitive than the measurement of platelet survival for the assessment of antiplatelet drug efficacy in patients with aortic grafts.
PubMed: 8165609
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Antithrombotic activity of Bay u3405, a thromboxane A2-antagonist, in patients with Dacron aortic grafts: a random controlled clinical trial.</title><author><name sortKey="Pieters, H" uniqKey="Pieters H">H Pieters</name><affiliation wicri:level="1"><nlm:affiliation>Department of Haematology, University of the Orange Free State, Bloemfontein, South Africa.</nlm:affiliation><country xml:lang="fr">Afrique du Sud</country><wicri:regionArea>Department of Haematology, University of the Orange Free State, Bloemfontein</wicri:regionArea></affiliation></author><author><name sortKey="Roodt, J P" uniqKey="Roodt J">J P Roodt</name></author><author><name sortKey="Badenhorst, P N" uniqKey="Badenhorst P">P N Badenhorst</name></author><author><name sortKey="Van Wyk, V" uniqKey="Van Wyk V">V van Wyk</name></author><author><name sortKey="Schall, R" uniqKey="Schall R">R Schall</name></author><author><name sortKey="L Tter, M G" uniqKey="L Tter M">M G Lötter</name></author><author><name sortKey="Hundt, H K" uniqKey="Hundt H">H K Hundt</name></author><author><name sortKey="Nel, C J" uniqKey="Nel C">C J Nel</name></author></titleStmt><publicationStmt><date when="1993">1993</date><idno type="RBID">pubmed:8165609</idno><idno type="pmid">8165609</idno><idno type="wicri:Area/Main/Corpus">004E17</idno><idno type="wicri:Area/Main/Curation">004E17</idno><idno type="wicri:Area/Main/Exploration">004D85</idno></publicationStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Aorta</term><term>Blood Platelets (cytology)</term><term>Blood Platelets (physiology)</term><term>Blood Vessel Prosthesis</term><term>Carbazoles (pharmacology)</term><term>Cell Survival</term><term>Double-Blind Method</term><term>Follow-Up Studies</term><term>Humans</term><term>Indium Radioisotopes (diagnostic use)</term><term>Male</term><term>Middle Aged</term><term>Platelet Adhesiveness (drug effects)</term><term>Polyethylene Terephthalates</term><term>Sulfonamides (pharmacology)</term><term>Thromboxane A2 (antagonists & inhibitors)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Thromboxane A2</term></keywords><keywords scheme="MESH" type="chemical" qualifier="diagnostic use" xml:lang="en"><term>Indium Radioisotopes</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Carbazoles</term><term>Sulfonamides</term></keywords><keywords scheme="MESH" qualifier="cytology" xml:lang="en"><term>Blood Platelets</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Platelet Adhesiveness</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Blood Platelets</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Aorta</term><term>Blood Vessel Prosthesis</term><term>Cell Survival</term><term>Double-Blind Method</term><term>Follow-Up Studies</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Polyethylene Terephthalates</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Twelve patients with Dacron aortic grafts participated in a placebo controlled, crossover trial to investigate the effect of Bay u3405, a thromboxane A2 receptor antagonist, on graft thrombogenicity. During each treatment period (seven days, Bay u3405 or placebo), 111In-platelet survival and platelet deposition on the grafts were measured daily by gamma-camera imaging and blood radioactivity analysis. Bay u3405 substantially reduced the deposition of platelets and the thrombogenic index, while platelet survival remained unchanged. The ex vivo platelet aggregation response to ADP and epinephrine was significantly inhibited. The bleeding time increased slightly but not to any clinically relevant extent, and no adverse side effects were recorded. Bay u3405 seems to be a safe and effective drug for the inhibition of platelet deposition on aortic Dacron grafts. The use of quantitative imaging techniques is also more sensitive than the measurement of platelet survival for the assessment of antiplatelet drug efficacy in patients with aortic grafts.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">8165609</PMID><DateCreated><Year>1994</Year><Month>05</Month><Day>23</Day></DateCreated><DateCompleted><Year>1994</Year><Month>05</Month><Day>23</Day></DateCompleted><DateRevised><Year>2012</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0340-6245</ISSN><JournalIssue CitedMedium="Print"><Volume>70</Volume><Issue>6</Issue><PubDate><Year>1993</Year><Month>Dec</Month><Day>20</Day></PubDate></JournalIssue><Title>Thrombosis and haemostasis</Title><ISOAbbreviation>Thromb. Haemost.</ISOAbbreviation></Journal><ArticleTitle>Antithrombotic activity of Bay u3405, a thromboxane A2-antagonist, in patients with Dacron aortic grafts: a random controlled clinical trial.</ArticleTitle><Pagination><MedlinePgn>903-8</MedlinePgn></Pagination><Abstract><AbstractText>Twelve patients with Dacron aortic grafts participated in a placebo controlled, crossover trial to investigate the effect of Bay u3405, a thromboxane A2 receptor antagonist, on graft thrombogenicity. During each treatment period (seven days, Bay u3405 or placebo), 111In-platelet survival and platelet deposition on the grafts were measured daily by gamma-camera imaging and blood radioactivity analysis. Bay u3405 substantially reduced the deposition of platelets and the thrombogenic index, while platelet survival remained unchanged. The ex vivo platelet aggregation response to ADP and epinephrine was significantly inhibited. The bleeding time increased slightly but not to any clinically relevant extent, and no adverse side effects were recorded. Bay u3405 seems to be a safe and effective drug for the inhibition of platelet deposition on aortic Dacron grafts. The use of quantitative imaging techniques is also more sensitive than the measurement of platelet survival for the assessment of antiplatelet drug efficacy in patients with aortic grafts.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pieters</LastName><ForeName>H</ForeName><Initials>H</Initials><Affiliation>Department of Haematology, University of the Orange Free State, Bloemfontein, South Africa.</Affiliation></Author><Author ValidYN="Y"><LastName>Roodt</LastName><ForeName>J P</ForeName><Initials>JP</Initials></Author><Author ValidYN="Y"><LastName>Badenhorst</LastName><ForeName>P N</ForeName><Initials>PN</Initials></Author><Author ValidYN="Y"><LastName>van Wyk</LastName><ForeName>V</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Schall</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Lötter</LastName><ForeName>M G</ForeName><Initials>MG</Initials></Author><Author ValidYN="Y"><LastName>Hundt</LastName><ForeName>H K</ForeName><Initials>HK</Initials></Author><Author ValidYN="Y"><LastName>Nel</LastName><ForeName>C J</ForeName><Initials>CJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType>Clinical Trial</PublicationType><PublicationType>Journal Article</PublicationType><PublicationType>Randomized Controlled Trial</PublicationType><PublicationType>Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>GERMANY</Country><MedlineTA>Thromb Haemost</MedlineTA><NlmUniqueID>7608063</NlmUniqueID><ISSNLinking>0340-6245</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Carbazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Indium Radioisotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Polyethylene Terephthalates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Sulfonamides</NameOfSubstance></Chemical><Chemical><RegistryNumber>57576-52-0</RegistryNumber><NameOfSubstance>Thromboxane A2</NameOfSubstance></Chemical><Chemical><RegistryNumber>P1ALI72U6C</RegistryNumber><NameOfSubstance>ramatroban</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y">Aorta</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Blood Platelets</DescriptorName><QualifierName MajorTopicYN="N">cytology</QualifierName><QualifierName MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y">Blood Vessel Prosthesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Carbazoles</DescriptorName><QualifierName MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Cell Survival</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Indium Radioisotopes</DescriptorName><QualifierName MajorTopicYN="N">diagnostic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Platelet Adhesiveness</DescriptorName><QualifierName MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y">Polyethylene Terephthalates</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Sulfonamides</DescriptorName><QualifierName MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Thromboxane A2</DescriptorName><QualifierName MajorTopicYN="Y">antagonists & inhibitors</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1993</Year><Month>12</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1993</Year><Month>12</Month><Day>20</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1993</Year><Month>12</Month><Day>20</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8165609</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=IndiumV2/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004D85 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004D85 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= *** parameter Area/wikiCode missing ***
|area= IndiumV2
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:8165609
|texte= Antithrombotic activity of Bay u3405, a thromboxane A2-antagonist, in patients with Dacron aortic grafts: a random controlled clinical trial.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:8165609" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a IndiumV2
| This area was generated with Dilib version V0.5.76. |  |